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O-linked oligosaccharides (O-glycans) are the 
primary components of the intestinal mucus 
layer that overlies the gastrointestinal epithelium. 
This layer is a dense, carbohydrate-rich matrix 
that consists primarily of mucins containing 
multiple serine and threonine residues, which 
have been modifi  ed by O-glycans and which 
account for 80% of the mucin mass (1–6). The 
mucus layer and epithelial cells comprise an in-
testinal barrier that protects epithelial and intes-
tinal mucosal immune cells from potentially 
harmful luminal microfl  ora and food compo-
nents (3–6) and participates in bacterial coloni-
zation (7). The role of intestinal epithelial cells 
in maintaining barrier function and in the 
pathogenesis of several common intestinal dis-
eases, such as infl  ammatory bowel disease (IBD) 
and colorectal cancer, has been well studied 
(8–15). However, the physiological and patho-
logical signifi  cance of the mucus layer has been 
less explored.
IBD is generally recognized as an immune-
mediated disorder resulting from an abnormal 
interaction between colonic microfl  ora and mu-
cosal immune cells in a genetically susceptible 
host (14, 16). How this interaction develops is not 
well understood. A deterioration of the mucus 
layer of the colon is prominent in   patients with 
ulcerative colitis, which is a common form of 
IBD (3–6). Altered intestinal O-glycan expres-
sion appears early in the pathogenesis of ulcer-
ative colitis (6). Interestingly, similarly altered 
O-glycans are seen in >90% of colorectal can-
cers, which have a close association with ulcer-
ative colitis (6, 17, 18). Whether or not this 
abnormal O-glycan expression contributes to the 
etiology of these diseases is unknown.
O-glycans containing GalNAc in α-linkage 
to serine or threonine residues occur on many 
membrane and secreted proteins, particularly 
mucins (1, 2). O-glycans have two main core struc-
tures, referred to as core 1– and core 3–derived 
O-glycans (Fig. 1 A). The biosynthesis of these 
cores is controlled by specifi  c   glycosyltransferases. 
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Altered intestinal O-glycan expression has been observed in patients with ulcerative colitis 
and colorectal cancer, but the role of this alteration in the etiology of these diseases 
is unknown. O-glycans in mucin core proteins are the predominant components of the 
intestinal mucus, which comprises part of the intestinal mucosal barrier. Core 3–derived 
O-glycans, which are one of the major types of O-glycans, are primarily expressed in the 
colon. To investigate the biological function of core 3–derived O-glycans, we engineered 
mice lacking core 3 𝗃1,3-N-acetylglucosaminyltransferase (C3GnT), an enzyme predicted 
to be important in the synthesis of core 3–derived O-glycans. Disruption of the C3GnT gene 
eliminated core 3–derived O-glycans. C3GnT-defi  cient mice displayed a discrete, colon-
specifi  c reduction in Muc2 protein and increased permeability of the intestinal barrier. 
Moreover, these mice were highly susceptible to experimental triggers of colitis and 
  colorectal adenocarcinoma. These data reveal a requirement for core 3–derived O-glycans 
in resistance to colonic disease.
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Core 3 β1,3-N-acetylglucosaminyltransferase (C3GnT) ac-
tivity is enriched in mucin-secreting epithelial tissues, such as 
gastrointestinal tract, as measured by enzymatic activity assays 
in tissue lysates (1, 2, 19, 20). The enzyme transfers GlcNAc 
from UDP-GlcNAc to GalNAcα1-Ser/Thr (Tn antigen) to 
form the core 3 O-glycan (GlcNAcβ1,3GalNAcα1-Ser/Thr), 
which can be further modifi  ed to form more complex struc-
tures, such as core 4 O-glycans (Fig. 1 A). Recently, human 
core C3GnT (also known as β3Gn-T6 or core 3 synthase) was 
identifi  ed (19, 20). In vitro biochemical analysis suggests that 
C3GnT is the only enzyme responsible for the biosynthesis of 
core 3 O-glycans (19, 20).
We hypothesized that core 3–derived O-glycans are a key 
constituent of the intestinal mucus layer and are important 
for intestinal barrier function, and that the alteration of core 3–
  derived O-glycan expression plays a role in the pathogenesis of 
common intestinal diseases, such as colitis and intestinal  tumors. 
To test these hypotheses, we created mice lacking core 3–
  derived O-glycans by targeted deletion of the C3GnT gene 
(C3GnT−/−). We found that deletion of the C3GnT gene 
eliminated core 3–derived O-glycans and signifi  cantly  re-
duced total intestinal glycans. Furthermore, C3GnT−/− mice 
exhibited an increased susceptibility to experimental colitis and 
colorectal adenocarcinoma. The results presented in this study 
indicate that core 3–derived O-glycans are key components of 
intestinal mucin, and that defects in their expression may be 
associated with the pathogenesis of colonic disease.
RESULTS
Molecular characterization of the murine C3GnT gene
A Mus musculus chromosome 7 genomic contig (NT_039433) 
that contains the C3GnT gene and a 2,370-bp, full-length 
murine cDNA sequence (XM_195661) were identifi  ed by 
BLASTN searches using the published human C3GnT nu-
cleotide sequence (19). The analyses indicated that murine 
C3GnT is a type II membrane protein with 68% identity 
to the human C3GnT (Fig. S1, available at http://www.jem
.org/cgi/content/full/jem.20061929/DC1). Southern blot 
analysis (unpublished data) confi  rmed that the murine C3GnT 
gene has two exons. Exon 1 comprises 36 bp that encode a 
5′-untranslated region. Exon 2 comprises 2,318 bp encoding 
the ATG translational start site, cytoplasmic domain, trans-
membrane domain, stem region, and the catalytic domain of 
C3GnT. RT-PCR of RNA extracted from diff  erent mouse 
tissues revealed that murine C3GnT mRNA is predomi-
nantly expressed in colonic tissue (Fig. S2 A). The ileum and 
the salivary glands also expressed low levels of C3GnT tran-
scripts, whereas the rest of the analyzed tissues had no C3GnT 
expression. To determine if the identifi  ed C3GnT gene con-
fers β1,3-N-acetylglucosaminyltransferase activity, we cloned 
the C3GnT cDNA into a baculovirus expression system (21). 
Enzymatic analysis indicated that recombinant murine C3GnT 
exhibited β1,3-N-acetylglucosaminyltransferase activity, which 
transfers GlcNAc from UDP-GlcNAc to GalNAcβ1α-R, thus 
confi  rming the identity of the cloned murine C3GnT gene 
(Fig. S2, B and C).
Generation of C3GnT−/− mice
To study the biological function of C3GnT, we generated 
mice lacking the C3GnT gene by targeted homologous re-
combination in mouse embryonic stem cells (Fig. 1, B and C) 
using previously described methods (22, 23). RT-PCR and 
enzymatic assays confi  rmed that C3GnT mRNA and C3GnT 
enzyme activity in tissue extracts were eliminated in C3GnT−/− 
mice (Fig. 1, D and E). To characterize the tissue expres-
sion pattern of endogenous C3GnT, we engineered a LacZ 
reporter gene immediately downstream of the C3GnT ATG 
translational start site. LacZ staining of diff  erent C3GnT−/− 
tissues confi  rmed that expression of C3GnT was restricted to 
colonic tissues (Fig. 1 F and not depicted). Although RT-PCR 
Figure 1.  Generation of C3GnT−/− mice. (A) The scheme shows the 
two major O-glycan branching pathways. C3GnT refers to C3GnT. Arrow-
heads show the possible pathways for further branching, elongation, 
  fucosylation, sialylation, and sulfation. (B and C) Strategy to generate mice 
lacking core 3–derived O-glycans by targeting the C3GnT gene, and 
Southern blot genotyping using EcoRV restriction enzyme digestion. 
(D) RT-PCR confi  rmed the deletion of the C3GnT gene product. GAPDH was 
used as an amplifi  cation control. (E) C3GnT enzymatic activity in C3GnT+/+ 
and C3GnT−/− tissues. Error bars represent the mean ± the SD. n = 3. 
(F) LacZ staining of C3GnT+/+ and C3GnT−/− colonic tissues. Bar, 100 μm.JEM VOL. 204, June 11, 2007  1419
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detected lower levels of endogenous C3GnT mRNA in the 
small intestine and salivary glands, lacZ staining was not detected 
in these tissues (unpublished data), which likely refl  ected 
sensitivity diff  erences between the two assays.
C3GnT−/− mice developed normally, and both sexes 
were fertile in a specifi  c pathogen-free barrier facility. Inter-
crosses between heterozygotes yielded normal-sized litters 
with Mendelian inheritance. C3GnT−/− mice had normal 
peripheral blood counts (unpublished data). Gross morphol-
ogy and histological examinations of 6–20-wk-old mice 
revealed no observable diff  erences between wild-type litter-
mates (C3GnT+/+) and C3GnT−/− mice in major organs, 
including heart, liver, salivary glands, stomach, jejunum, 
  ileum, colon, spleen, thymus, and lymph nodes (Fig. S3 and 
Fig. S4 A, available at http://www.jem.org/cgi/content/full/
jem.20061929/DC1; and not depicted). Flow cytometry of 
C3GnT−/− peripheral blood cells and splenocytes revealed 
no substantial abnormalities in the absolute number and the 
ratios of CD3+ T cells (including CD4+, CD8+, and innate-
like invariant NKT cells) and of CD19+ B cells (including 
innate-like marginal zone B cells; Fig. S4 B and not depicted). 
This suggests that the defi  ciency of core 3–derived O-glycans 
does not aff  ect the development of immune cells.
Disruption of the C3GnT gene eliminates core 3–derived 
O-glycans and exposes the Tn antigen in murine colon
We used matrix-assisted laser desorption/ionization time-of-
fl  ight mass spectrometry (MALDI-TOF-MS) to defi  ne the 
O-glycan structures in C3GnT+/+ and C3GnT−/−  colon (24). 
Consistent with previous data, both core 1– and core 3–derived 
O-glycans (core 3 O-glycans, fucosylated core 3 O-glycans, 
and core 4 O-glycans) were dominant structures expressed in 
the C3GnT+/+ colon (Fig. 2 A and Fig. S5, available at http://
www.jem.org/cgi/content/full/jem.20061929/DC1) (2, 19, 
20, 22). Structural analysis revealed that C3GnT−/− colonic 
tissue did not express core 3–derived O-glycans (Fig. 2 A and 
Fig. S5). These results confi  rmed the deletion of the C3GnT 
gene and provide defi  nitive evidence that the C3GnT gene 
encodes the predominant C3GnT activity.
C3GnT catalyzes the formation of core 3–derived O-
  glycans by adding GlcNAc to its substrate GalNAc-α-Ser/Thr 
(Tn antigen), which is normally modifi  ed with one or more 
other monosaccharides (Fig. 1 A) (1, 19). We expected that 
the deletion of the C3GnT gene would expose Tn antigen in 
C3GnT−/− intestinal tissues. As predicted, immunochemical 
staining with anti-Tn mAb did not label C3GnT+/+ intesti-
nal tissue. In contrast, anti-Tn mAb labeled C3GnT−/− in-
testinal epithelial cells, but not other cell types (Fig. 2 B). 
Enzymatic desialylation of tissue sections did not enhance 
binding of anti-Tn to C3GnT−/− tissues, suggesting that si-
alic acid does not appreciably modify the exposed Tn antigen 
to form the sialyl-Tn antigen (Fig. 1 A) in C3GnT−/− co-
lonic tissue. However, enzymatic desialylation revealed the 
Tn antigen in C3GnT+/+ colonic tissue, indicating that the 
sialyl-Tn antigen is normally expressed in wild-type mouse 
colon (Fig. 2 B).
We then used periodic acid-Schiff  ’s reagent (PAS) and 
Alcian blue to determine if the defi  ciency of core 3–derived 
O-glycans aff  ects the expression of intestinal glycans. PAS 
stains neutral carbohydrates, whereas Alcian blue recognizes 
acidic carbohydrates that may represent sialylated, fucosyl-
ated, or sulfated sugars. PAS and Alcian blue staining re-
mained unchanged in the jejunum and the ileum of both 
C3GnT+/+ and C3GnT−/− mice (Fig. S6, available at http://
www.jem.org/cgi/content/full/jem.20061929/DC1). How-
ever, both PAS staining and Alcian blue staining were signifi  -
cantly reduced in the colons of C3GnT−/− mice compared 
with those of C3GnT+/+ mice (Fig. 2, C and D). Consistent 
with the RT-PCR and lacZ staining data, this result demon-
strates that core 3–derived O-glycans are predominantly ex-
pressed in mouse colon.
Figure 2.  Disruption of the C3GnT gene eliminates core 3–derived 
O-glycans and exposes the Tn antigen in murine colons. (A) Annotated 
spectra of matrix-assisted laser desorption/ionization time-of-fl  ight mass 
spectrometry (MALDI-TOF-MS) analyses of 2-AB–labeled O-glycans of 
C3GnT+/+ and C3GnT−/− colons in a linear-positive mode. Each annotated 
molecular mass of O-glycan includes masses of a 2-AB and a Na. Asterisks 
represent positions of core 3–derived O-glycans that are missing in 
C3GnT−/− mice. Data are representatives of three experiments. (B) Immuno-
histochemical staining of mouse colon tissue sections with a mAb to the 
Tn antigen. The sections were pretreated with or without sialidase. Brown 
reaction products mark sites of antibody binding. Data are representatives 
of at least three experiments. (C) C3GnT+/+ and C3GnT−/− colonic tissues 
stained with PAS (pink color) and Alcian blue (blue color). (D) Pixels of PAS 
and Alcian blue staining areas were quantifi  ed by Photoshop software 
based on six sections of three independent mice from each group. Error 
bars represent the mean ± the SD. Bars: (B) 50 μm; (C) 100 μm.1420  INTESTINAL FUNCTION REQUIRES CORE 3 O-GLYCOSYLATION | An et al.
Defi  ciency of C3GnT results in reduced Muc2 expression 
in colon and impaired mucosal integrity
To investigate if a defi  ciency of core 3 O-glycosylation af-
fects the expression of intestinal mucins, we fi  rst screened the 
mRNA levels of the major intestinal mucins by semiquantita-
tive RT-PCR. We observed no signifi  cant diff  erences between 
C3GnT+/+ and C3GnT−/− colons in mRNA levels of Muc2, 
Muc3, Muc13, and Muc5ac (Fig. S7 A, available at http://
www.jem.org/cgi/content/full/jem.20061929/DC1). How-
ever, probing with a glycosylation-independent polyclonal 
antibody revealed a substantial reduction of Muc2 protein, 
which is the predominant component of the intestinal mu-
cous layer (3–6, 18, 25) in C3GnT−/− colonic tissue (Fig. 3, A 
and B). We questioned whether the decreased expression of 
Muc2 was caused by a reduced numbers of goblet cells. How-
ever, immunohistochemistry of C3GnT+/+ and C3GnT−/− 
colon tissues revealed similar expression of intestinal trefoil fac-
tor (ITF), which is a nonmucin protein and a product of fully 
diff  erentiated goblet cells (Fig. 3, A and B) (26). In addition, 
Alcian blue staining and transmission electron microscopic 
  imaging revealed no considerable morphological diff  erence 
between C3GnT+/+ and C3GnT−/− goblet cells (Fig. S7, 
B and C). Thus, goblet cells are preserved in the C3GnT−/− 
  colon, but goblet cell production of Muc2 is reduced. We 
were unable to examine protein expression of other, less-
  expressed, intestinal mucins because of the lack of glycosylation-
independent antibodies to these murine glycoproteins.
To investigate if the loss of core 3–derived O-glycans af-
fects mucosal integrity, we fed C3GnT+/+ and C3GnT−/− 
mice with FITC-dextran by gavage, and 4 h later we mea-
sured their serum levels of FITC-dextran to evaluate intestinal 
permeability. Serum levels of FITC-dextran in C3GnT−/− mice 
were signifi  cantly higher than in C3GnT+/+ mice (Fig. 3 C). 
Fluorescent microscopic analysis of the C3GnT+/+ and 
C3GnT−/− intestinal cryosections revealed no fl  uorescent 
infi   ltration of FITC-dextran into both C3GnT+/+ and 
C3GnT−/− small intestinal villi. In contrast, a higher level of 
fl  uorescent intensity was observed in C3GnT−/− colonic tis-
sues compared with that in C3GnT+/+ tissues (Fig. 3 D). 
Collectively, these data indicate that colonic mucosal integ-
rity is impaired in C3GnT−/− mice.
We reasoned that the defi  ciency of core 3 O-glycans and 
the impairment in mucosal integrity might result in an altera-
tion of mucosa-associated bacteria in C3GnT−/− mice. We 
used 16S bacterial ribosomal DNA (rDNA)–based real-time 
PCR analysis to address this question. Two sets of universal 
16S rDNA primers (16S1 and 16S2) reproducibly detected a 
signifi  cant increase in 16S rDNA in C3GnT−/− colonic tissues 
in comparison to that in C3GnT+/+ colonic tissues (Fig. 3 E). 
The increase is not likely caused by variations in luminal bac-
terial fl  ora because the amount of 16S rDNA in C3GnT+/+ 
and C3GnT−/− fecal material was similar (Fig. 3 E). Mesen-
teric nodes had weak, yet detectable, 16S rDNA signal, but 
there was no diff  erence between C3GnT+/+ and C3GnT−/− 
groups (unpublished data). Mesenteric bacterial translocation 
is associated with traffi   cking of bacteria-bearing dendritic cells 
from the mucosa, typically after Toll-like receptor sensing or 
other immune activation (27, 28). Thus, no detectable in-
crease in bacterial translocation in C3GnT−/− mesenteric 
nodes is consistent with the lack of spontaneous colonic in-
fl  ammation in C3GnT−/− mice.
C3GnT−/− mice are highly susceptible to dextran sodium 
sulfate (DSS)–induced colitis
DSS is a chemical commonly used to induce experimental 
colitis (29). We examined the pathological consequence of 
Figure 3.  C3GnT−/− colon has reduced expression of Muc2 and 
impaired mucosal integrity. (A) Immunohistochemical staining of C3GnT+/+ 
and C3GnT−/− colonic tissues with an anti-murine Muc2 peptide antibody 
and with an antibody to ITF, which is a marker of fully differentiated goblet 
cells. Brown color indicates specifi  c antibody binding. (B) Pixels of positive 
staining area per crypt were quantifi  ed using Photoshop. Six sections of 
three independent mice from each group were quantifi  ed. Error bars repre-
sent the mean ± the SD. (C) Serum concentration of the FITC-dextran of 
C3GnT+/+ and C3GnT−/− mice were measured 4 h after oral administration 
of FITC-dextran. Error bars represent the mean ± the SD. n = 6. (D) Repre-
sentative images of fl  uorescent microscopic analysis of C3GnT+/+ and 
C3GnT−/− intestinal cryosections 4 h after oral administration of FITC-
  Dextran (three sections from each mouse, with four mice in each group). 
(E) Relative amount of 16S rDNA detected by real-time PCR using two 
  independent sets of 16S universal primers. Data are expressed as an n-fold 
difference between C3GnT+/+ and C3GnT−/− mice. Error bars represent the 
mean ± the SD. n = 6 mice in each group. The average 16S rDNA value of 
C3GnT+/+ mice was expressed as 1. Bars: (A) 100 μm; (D) 50 μm.JEM VOL. 204, June 11, 2007  1421
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the defi  ciency of core 3 O-glycosylation using this model. 
We fi  rst challenged 6-wk-old C3GnT+/+ and C3GnT−/− 
males with 2.5% DSS in drinking water for 14 d to deter-
mine its lethality rate. We found that 9/10 C3GnT+/+ mice 
survived the treatment, whereas all C3GnT−/− mice died at 
the end of the 14-d treatment (Fig. 4 A). We then treated 
6-wk-old C3GnT+/+ and C3GnT−/− males with 2% DSS 
in drinking water for 7 d, followed by 4 d of water with-
out DSS. These experimental conditions induced colitis in 
both C3GnT+/+ and C3GnT−/− mice. However, the coli-
tis in the C3GnT−/− mice was markedly more severe, with 
greater weight loss, diarrhea, fecal bleeding, and shortened 
colon length (Fig. 4, B–D, and Fig. S8, available at http://
www.jem.org/cgi/content/full/jem.20061929/DC1). The 
infl  ammation was restricted to the colon, especially in the 
distal colonic region, whereas the small intestine was not 
substantially aff  ected (Fig. S3). Histological examination 
showed that both C3GnT+/+ and C3GnT−/− colonic tis-
sues appeared normal before DSS treatment. However, after 
2% DSS treatment, C3GnT−/− mice had more severe crypt 
destruction, larger areas of epithelial ulceration, erosions, and 
massive infl  ammatory cell infi  ltration into the mucosal tissue 
(Fig. 4, E and F).
To characterize the infi  ltrating infl  ammatory cells asso-
ciated with DSS-induced colitis, we probed C3GnT+/+ and 
C3GnT−/− colonic tissues with anti-CD3 antibody to iden-
tify T lymphocytes and anti-F4/80 antibody to identify 
monocytes/macrophages. Compared with C3GnT+/+ mice, 
there was a dramatic increase of both T cells and monocytes/
macrophages in the lamina propria of C3GnT−/− mice (Fig. 
5, A and B).
To further understand the immunological features of 
DSS-induced colitis in C3GnT−/− mice, we evaluated intra-
cellular production of the cytokines IL-2, IL-17, IFN-γ, and 
TNF-α in splenocytes (30). Compared with DSS-treated 
C3GnT+/+ mice, splenic CD4 T cells from DSS-treated 
C3GnT−/− mice exhibited modestly elevated levels of IL-2, 
IFN-γ, and TNF-α, suggesting that eff  ector activation of 
CD4+ T cells associated with DSS-induced mucosal infl  am-
mation is greater in C3GnT−/− mice (Fig. 5 C).
C3GnT−/− mice are highly susceptible to DSS-induced 
colitis. We speculated that C3GnT−/− intestinal mucosal 
lymphocytes might be activated because of an impaired 
mucosal barrier function, even in the absence of DSS chal-
lenge. We thus examined TNF-α, IFN-γ, IL-17, and IL-6 
expression in intraepithelial lymphocytes (IELs) and lamina 
propria lymphocytes (LPLs) from colons of C3GnT+/+ and 
C3GnT−/− mice without DSS treatment. Notably, the ex-
pression of the proinfl  ammatory cytokines TNF-α, IFN-γ, 
and IL-17 by CD3+ IELs and LPLs was signifi  cantly  in-
creased in C3GnT−/− mice as compared with C3GnT+/+ 
mice (Fig. 5 C). This suggests an infl  ammation-prone status 
in intestines of C3GnT−/− mice. Interestingly, IL-6 expres-
sion was increased in the IELs of C3GnT−/− mice (Fig. 5 D), 
which may contribute to the increased susceptibility to colo-
rectal tumor in the mice (31).
Accelerated colorectal tumorigenesis in C3GnT−/− mice 
after azoxymethane (AOM) and DSS treatment
Patients with ulcerative colitis exhibit increased risk of colo-
rectal cancer (32, 33). Abnormal O-glycans such as the Tn 
antigen are expressed in >90% of colorectal cancers, but are 
absent in normal colonic mucosa (6, 17). Thus, we explored 
whether mice lacking core 3 O-glycans are susceptible to co-
lorectal tumorigenesis. We used the well-established AOM/
DSS model (34). 12 or 20 wk after AOM/DSS treatment, 
C3GnT−/− colon and rectum exhibited a fi  vefold increase 
in tumor volume (Fig. 6, A and B). Occasionally, small ade-
nomas were found in the proximal colon, but no tumors were 
observed in the cecum, ileum, and jejunum of C3GnT+/+ or 
C3GnT−/− mice (unpublished data). Histologically, most le-
sional tissues were composed of proliferating adenomatous 
columnar epithelium with prominent architectural and cy-
tological atypia. The changes were consistent with tubular 
adenoma featuring extensive high-grade dysplasia (intramu-
cosal carcinoma). In C3GnT−/− mice, 20 wk after treatment, 
Figure 4.  C3GnT−/− mice have more severe DSS-induced colitis. 
(A) Survival rate of a cohort of 10 age-matched C3GnT+/+ and C3GnT−/− 
males after a 14-d, 2.5% DSS treatment. (B–D) Percent body weight 
changes compared with baseline, diarrhea score, and fecal blood score in 
6-wk-old C3GnT+/+ and C3GnT−/− males after a 7-d, 2% DSS treatment. 
Each point represents the mean ± the SEM. n = 10. (E) Hematoxylin and 
eosin–stained colonic tissues of C3GnT+/+ and C3GnT−/− mice with or 
without 2% DSS treatment. Bar, 100 μm. (F) Histopathological scores of 
C3GnT+/+ and C3GnT−/− mice 7 d after 2% DSS treatment based on degrees 
of infl  ammatory cell infi  ltration and epithelial injury. Error bars indicate 
mean ± the SEM. n = 12.1422  INTESTINAL FUNCTION REQUIRES CORE 3 O-GLYCOSYLATION | An et al.
some of the adenomas progressed to adenocarcinomas that 
invaded muscularis mucosae and submucosa (Fig. 6 C).
To investigate the cellular mechanisms by which a defi  -
ciency of core 3–derived O-glycans aff  ects colorectal tumori-
genesis, we used bromodeoxyuridine (BrdU) metabolic labeling 
to examine the rate of colonic epithelial proliferation (25). 3 h 
after BrdU intraperitoneal injection, the number of BrdU-
positive colonic epithelial cells per crypt in C3GnT−/− mice was 
signifi  cantly greater than those in C3GnT+/+ mice with or 
without AOM/DSS treatment (Fig. 6 D). These results indi-
cate that the absence of core 3–derived O-glycans increases co-
lonic epithelial cell proliferation in C3GnT−/− mice.
Wnt signaling is one of the key signaling pathways in colo-
rectal cancer development in humans (35). Western blot analy-
sis showed that the expression of β-catenin and TCF4, which 
are components of the Wnt pathway, was signifi  cantly greater 
in tumor and nontumor colon tissue extracts from C3GnT−/− 
mice (Fig. 6 E). C3GnT−/− tissues also had much more cyclin 
D1 and c-myc, which are downstream targets of β-catenin and 
TCF-4. Immunohistochemistry revealed strong nuclear trans-
location of β-catenin in C3GnT−/− tumor tissues (Fig. 6 F). 
These data suggest that the molecular mechanism of tumori-
genesis in C3GnT−/− mice is similar to that in humans.
D  I  S  C  U  S  S  I  O  N 
To investigate the function of core 3–derived O-glycans, we 
generated mice with a targeted deletion of the C3GnT gene. 
Disruption of the gene eliminated core 3–derived O-glycans 
in the mouse colon, resulting in reduced expression of Muc2 
and increased intestinal barrier permeability. Furthermore, 
C3GnT−/− mice exhibited increased susceptibility to DSS-
induced colitis and AOM/DSS-induced colorectal adenocarci-
nomas. These data demonstrate the importance of core 3–derived 
O-glycans in intestinal function.
Figure 5.  C3GnT−/− colon has increased infi  ltration of T lympho-
cytes and monocytes/macrophages, and C3GnT−/− CD4 T cells have 
increased intracellular expression of IL-2, IFN-𝗄, and TNF-𝗂 after 
2% DSS treatment. (A) CD3-positive lymphocyte (green) or F4/80-
  positive monocyte/macrophage (red) infi  ltrates C3GnT+/+ and C3GnT−/− 
colon after 2% DSS treatment. Bar, 50 μm. (B) Positive staining areas were 
quantifi  ed as pixels per high-powered microscopic fi  eld (20×) using 
  Photoshop based on six sections from three independent mice from each 
group. Error bars indicate the mean ± the SD. (C) Flow cytometric analysis 
of intracellular cytokine expression in splenic CD4+ T cells isolated 
from either C3GnT+/+ or C3GnT−/− mice after 2% DSS treatment. The 
plots were gated on CD3+ population. The number in each image indi-
cates the percentage of CD4+ T cells. This result is representative of 
data of three experiments (three C3GnT+/+ and three C3GnT−/− mice in 
each experiment). (D) Flow cytometric analysis of intracellular cytokine 
expression in CD3+ IEL and LPL isolated from the colon of C3GnT+/+ or 
C3GnT−/− mice without DSS treatment. The number in each image indi-
cates the percentages of cytokine-expressing CD3+ cells. This result is 
representative of data of age-matched males in the 129/SvlmJ back-
ground (three C3GnT+/+ and four C3GnT−/− mice).JEM VOL. 204, June 11, 2007  1423
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Factors controlling O-glycan structure in the colon
Unlike core 1-derived O-glycans that are present in most tis-
sues (1, 22), core 3–derived O-glycans are expressed predom-
inantly in colonic epithelial cells (demonstrated here by lacZ 
reporter staining in C3GnT−/− mice), implying an important 
function in colon. Our MALDI-TOF-MS analyses indicated 
that disruption of the C3GnT gene eliminated all core 3–
derived O-glycans, including core 4, and other core 3–derived 
O-glycan variants. These data provide defi  nitive evidence 
that C3GnT gene encodes all measurable C3GnT activity. 
This distinguishes C3GnT from many glycosyltransferases 
that usually exist as multigene families with related structures 
and functions (1, 2). Interestingly, the common core 1 O-glycan 
Galβ1,3GalNAcα1-Ser/Thr is generated by the activity of 
the core 1 β1,3-galactosyltransferase (T-synthase), which, like 
C3GnT, is also encoded by a single gene (36).
Tn antigen (GalNAcα-O-Ser/Thr), which is the only 
structure common to all mucin-type O-glycans, is normally 
hidden because it is a substrate for diff  erent types of additional 
glycosylation. These include sialylation to form the sialyl-Tn 
antigen or extensions to form core 1– or core 3–derived O-
glycans (Fig. 1 A). As expected, we found that defi  ciency of 
C3GnT resulted in the exposure of Tn antigen. Desialylation 
did not enhance Tn expression, indicating that sialic acid did 
not cap most of the exposed Tn antigens to form the sialyl-Tn 
antigen. Furthermore, HPLC and MALDI-TOF-MS analyses 
demonstrated that the absence of core 3–derived O-glycans 
did not cause compensatory increase in the biosynthesis of 
core 1-derived O-glycans (Fig. 2 A and not depicted). These 
data are consistent with our previous observation that the Tn 
antigen, which was exposed by global targeted deletion of core 
1–derived O-glycans, was not modifi  ed by sialylation during 
mouse embryonic development (22).
Mouse colon expresses enzymes to generate both core 1– and 
core 3–derived O-glycans, and expresses α2,6-sialyltransferase 
that modifi  es the Tn antigen (1, 2, 19, 22). Therefore, our data 
argue against the idea that the formation of core 1 and core 3 
O-glycans may compete because both types of O-glycans share 
Tn antigen as a substrate, and that exposed Tn antigens are al-
ways modifi  ed by sialylation. Such notions have been suggested 
as potential mechanisms for the aberrant expression of some 
cancer cell-related O-glycan antigens (20). Our data suggest 
that substrate specifi  cities of the glycosyltransferases for core 1 
or core 3 O-glycans may be determined not only by the Tn 
antigen, but also by other factors, such as rate-limiting enzy-
matic activity, sequence of the acceptor peptide, or neighbor-
ing glycosylation, as exhibited by some of the UDP-GalNAc:
polypeptide N-acetylgalactosaminyltransferases (37).
Core 3 O-glycans and colitis
Ulcerative colitis is limited to the colon, and typically presents 
in the rectum, where the mucus layer is the most elaborate 
Figure 6.  Accelerated colorectal tumorigenesis in C3GnT−/− mice 
after AOM/DSS treatment. (A) Representative luminal views of C3GnT+/+ 
and C3GnT−/− colons. Arrows indicate tumors. (B) Quantification 
of colonic tumor volume in C3GnT+/+ and C3GnT−/− mice. Error bars 
represent the mean ± the SD. n = 7. (C) Representative histopathological 
features of colorectal adenocarcinomas in C3GnT−/− mice. Arrowhead 
points to invasive neoplastic glands. Dashed lines depict the muscularis 
mucosae. (D) Quantifi  cation of BrdU-labeled proliferating colonic epithelial 
cells of C3GnT+/+ and C3GnT−/− mice with or without AOM/DSS 
  treatments. Error bars indicate the mean ± the SD. n = 5. (E) Expression 
of β-catenin, TCF-4, c-myc, and cyclin-D1 in C3GnT+/+ and C3GnT−/− 
colonic tissues measured by Western blots. β-Actin was used as a loading 
control. The data represent at least three experiments. (F) Immunohisto-
chemical staining illustrates nuclear localization of β-catenin in C3GnT−/− 
colonic neoplastic tissues (dark brown, arrows), whereas the nuclei 
of control normal epithelial cells had no β-catenin staining (white 
  arrowheads). The data are representative of at least three experiments. 
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(3–6, 38, 39). Although the factors responsible for this re-
gional variation are unknown, the deterioration of the mucus 
layer of the colon is prominent in ulcerative colitis. Indeed, 
the impaired expression of mucins has long been documented 
in patients with ulcerative colitis (3–5, 18, 38, 39). The ex-
pression of Muc2, which is the primary component of co-
lonic mucus layer, is lower in patients with active ulcerative 
colitis (6, 40). Truncated intestinal O-glycans, such as Tn an-
tigen, are also detected in patients with ulcerative colitis and 
are associated with abnormal mucin expression (6, 17, 18). 
In such clinical studies, it is diffi   cult to ascertain whether 
mucin defi  ciency or altered O-glycan expression is causal 
or is secondary to infl  ammation. The relationship between 
impaired mucin expression and altered O-glycans has also 
been unclear. Recently, the possibility that impaired mucin 
production is a causal factor in colitis was supported by 
  targeted deletion of the gene encoding Muc2 in mice, 
which developed spontaneous colitis and more severe DSS-
induced colitis (41).
Our study adds a new dimension to this theme by dem-
onstrating that a qualitative change of O-glycan in colonic 
mucin is suffi   cient to increase susceptibility to colitis, as well 
as to colorectal tumorigenesis. Unlike the recent report on 
Muc2−/− mice (41), C3GnT−/− mice did not undergo sponta-
neous colitis, and their infl  ammatory response to DSS was 
manifested more by mononuclear infl  ammation than by 
crypt abscesses. These diff  erences may refl  ect distinct eff  ects 
of quantitative vs. qualitative Muc2 abnormalities on the 
colonic mucosal response to injury. Quantitatively, Muc2 
protein levels in the absence of core 3 O-glycans were re-
duced, but still reached  40% of native levels. The function 
of this residual Muc2 protein may be suffi   cient to protect 
mice from spontaneous colitis. However, it should also be 
noted that genetic background and environmental factors, 
such as resident microbiota, contribute to the colitis pheno-
type in genetically susceptible mice (42). Indeed, spontane-
ous colitis in Muc2−/− mice appeared to depend on the 
129SV genetic background, as it was not observed in the 
initial description of the Muc2−/− mice on the C57BL6/
129SV mixed background (25, 41). Most C3GnT−/− mice 
used in this study were in a C57/BL6-129/SvlmJ mixed 
background, which may contribute to the variations in the 
colitis phenotype.
The increased DSS susceptibility of C3GnT−/− mice sug-
gests that altered O-glycosylation is a causal factor for ab-
normal mucin expression in colitis. Abnormal expression of 
O-glycans may change mucin intracellular traffi   cking and se-
cretion, or may increase access to proteolytic degradation. 
Alterations in the structure or expression of glycosyltransfer-
ases have been implicated in the etiology of several human 
diseases (1, 2, 43). Dysregulated expression or genetic muta-
tions of the C3GnT gene might contribute to the pathogen-
esis of some patients with ulcerative colitis. Genome-wide 
scans have identifi  ed some loci that are associated with IBD 
susceptibility. No genes regulating O-glycosylation have 
yet been identifi  ed in the known IBD loci (44). However, 
glycosylation pathways are complex, and they are sometimes 
promoted by enzymes or factors that function indirectly (1, 21). 
For example, the activity of T-synthase, which is a key enzyme 
for core 1–derived O-glycans, is dependent on a unique mo-
lecular chaperone called Cosmc (21). Thus, strategies focus-
ing on the variety of genes controlling O-glycosylation may 
test whether they represent genetic risk factors for ulcerative 
colitis and colorectal cancer.
It is not yet known whether patients with ulcerative coli-
tis or colorectal cancer have impaired mucin formation as a 
primary trait or as a secondary response to infl  ammation (3–5, 
17, 18, 38, 39). Our fi  ndings indicate that, in either context, 
such an impairment undermines mucosal resistance to in-
fl  ammation and to carcinogenesis. A recent study suggested 
that dysfunction of the intestinal epithelial barrier is the pri-
mary cause of SAMP ileitis susceptibility (45). Our results 
underscore an etiologic role of intestinal barrier function in 
the pathogenesis of IBD.
Enhanced Escherichia coli adherence and invasion has been 
found in Crohn’s disease and colon cancer, presumably be-
cause of altered mucosal glycosylation (46). We found that 
bacterial 16S rDNA was also increased in C3GnT−/− colonic 
issues, suggesting that lack of core 3–derived O-glycans causes 
either an enhanced adherence of bacteria to colonic mucosa 
or an increase in translocation of bacteria into colonic mucosa. 
Notably, the expression of several proinfl  ammatory cytokines 
was increased in C3GnT−/− mucosal lymphocytes from mice 
that did not receive DSS. This result indicates that defi  ciency 
of core 3–derived O-glycans may result in abnormal inter-
actions of intestinal microorganisms and/or their products with 
mucosal immune cells, may perturb mucosal immune homeo-
stasis, and may thus render C3GnT−/− mice more susceptible 
to DSS challenge. Moreover, the infl  ammatory products of 
these cells have been mechanistically linked to increased epi-
thelial permeability through activation of epithelial myosin 
light chain kinase (47, 48). Accordingly, conditions that re-
duce barrier integrity and increase infl  ammation may promote 
susceptibility to colitis and infl  ammation-dependent epithe-
lial neoplasia.
The immunologic response to DSS injury in C3GnT−/− 
mice included modest TH1 skewing (IL-2, IFN-γ, and 
TNF-α), but progressed to neither TH17 nor TH2 immune 
colitis. This distinguishes C3GnT−/− mice from models of 
TH1 or TH17 colitis (42, 49, 50). In this respect, Muc2−/− 
and C3GnT−/− mice may represent diff  erent facets of the in-
fl  am  mation that is associated with human ulcerative colitis. 
The relatively modest immune infl  ammatory components 
in Muc2−/− and C3GnT−/− mice suggest that defi  ciencies in 
mucus layer integrity alone are insuffi   cient to drive immune 
colitis, without the contribution of additional traits aff  ecting 
innate immune function or immunoregulation (42).
Glycosylation regulates lymphocyte traffi   cking, and mice 
transgenic for human α1,2-fucosyltransferase exhibit colitis as 
a result of defective T cell development resulting from altered 
lymphocyte glycosylation (51). However, it is unlikely that the 
C3GnT−/− phenotypes are caused by abnormal glycosylation JEM VOL. 204, June 11, 2007  1425
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of lymphocytes because core 3–derived O-glycans are not 
expressed in hematopoietic cells (19). In addition, the im-
mune organs of thymus and spleen of C3GnT−/− mice were 
normal, and C3GnT−/− peripheral blood had a normal distri-
bution of various lymphocyte subsets. These data provide no 
evidence that core 3–derived O-glycans cause abnormal sys-
temic immune development.
Core 3 O-glycans and carcinogenesis
The biologic mechanisms linking mucin abnormalities with 
colitis and carcinogenesis are not well understood. Altered 
core 3 O-glycosylation may impair intestinal mucus integrity, 
allowing abnormal interaction of intestinal luminal contents 
and commensal microfl  ora with mucosal immune cells. In-
creased intestinal permeability observed in C3GnT−/− mice 
supports this possibility. In addition, loss of core 3–derived 
O-glycans may cause an alteration in the variety and/or the 
density of intestinal commensal microfl  ora. Thus, compro-
mised intestinal homeostasis may result in chronic activation 
of mucosal immune cells in C3GnT−/− mice, even without 
challenge. Elevated expression of TNF-α, IFN-γ, and IL-6 
in the C3GnT−/− IELs and LPLs supports this hypothesis. In 
addition, the increases in lamina propria CD4+ T cells and 
macrophages and in splenocyte cytokine production suggest 
that the immune-mediated response to intestinal injury is 
  increased after DSS challenge in C3GnT−/− mice. Products 
of these and other immune cell types can induce abnormal 
epithelial cell growth and survival that contribute to carcino-
genesis (9, 52).
Greater epithelial cell proliferation in C3GnT−/− mice 
was observed even in the absence of AOM/DSS treatment. 
Thus, growth and survival characteristics of C3GnT−/− epi-
thelial cells may respond to increased constitutive exposure to 
luminal contents, altered commensal microbial composition, 
or the products that they induce in the local resident mucosal 
cells. This is comparable to mice impaired in epithelial barrier 
function because of defi  ciency of the multiple drug resistance 
type 1 gene, which also display spontaneous colitis and colonic 
dysplasia, particularly in the presence of intestinal injury or 
certain bacterial colonists (33, 53–55). Also, down-regulation 
of C3GnT expression has been observed in colon carcinoma 
(20), which may indicate that this trait could be a feature of 
some epithelium at risk for carcinogenesis. The altered expres-
sion of β-catenin/TCF-4, c-myc, and cyclin D1 observed 
during carcinogenesis in C3GnT−/− mice relates its molecu-
lar pathogenesis to that commonly observed in human colo-
rectal cancer (35).
In summary, we have discovered that C3GnT-defi  cient 
mice lack core 3–derived O-glycans, exhibit impaired Muc2 
expression primarily in colonic tissues, and are highly suscep-
tible to chemical-induced colitis and colorectal tumorigenesis. 
These data underscore an important in vivo role of core 3–
derived O-glycans in intestinal function. The C3GnT−/− 
mice should be useful to dissect how mucus layer integrity 
can be manipulated to promote or prevent chronic colitis and 
colorectal carcinogenesis. Because core 1–derived O-glycans 
are also a major component of intestinal mucus, generation of 
mice specifi  cally lacking intestinal core 1–derived O-glycans 
and mice lacking both core 1– and core 3–derived O-glycans 
will be valuable to evaluate the overall contribution of O-
glycans to intestinal function and to pathogenesis of common 
intestinal diseases.
MATERIALS AND METHODS
Generation of C3GnT−/− mice. Based on published human C3GnT 
DNA and amino acid sequences, National Center for Biotechnology In-
formation database searches were used to identify the corresponding mu-
rine C3GnT gene. We generated conventional C3GnT gene-defi  cient 
mice (C3GnT−/−), as illustrated in Fig. 1 B, by targeted homologous re-
combination in murine CJ7 embryonic stem cells (129/SvlmJ origin) using 
previously described methods (22, 23). In the gene-targeting construct, a 
neomycin selection marker was used to replace the major part of the coding 
exon 2 of C3GnT gene (Fig. 1 B). Because there is no available antibody or 
other molecular probe to C3GnT or core 3 O-glycans, a lacZ reporter was 
genetically integrated immediately after the endogenous C3GnT promoter 
region to characterize the expression pattern of C3GnT (Fig. 1 B). Geno-
types of mice were initially verifi  ed by Southern blotting and then routinely 
determined by PCR of genomic DNA from tail biopsies. RT-PCR was 
used to measure C3GnT mRNA transcripts.
Unless specifi  ed, 6-wk-old C3GnT−/− male mice in the 129/SvlmJ and 
C57BL/6J mixed background were used for experiments. Wild-type litter-
mates (C3GnT+/+) were used as controls. All mouse experiments were per-
formed in compliance with protocols approved by the Institutional Animal 
Care and Use Committees of the Oklahoma Medical Research Foundation 
and the University of California.
LacZ staining. 5-μm-thick cryosections of diff   erent tissues from 
C3GnT−/− mice were stained for lacZ based on the previously published 
method (56). In brief, sections on slides were treated with cold 0.2% glutar-
aldehyde in PBS for 10 min and rinsed three times with lacZ wash buff  er 
(2 mM MgCl2, 0.01% sodium deoxycholate, and 2.5% Nonidet-P40 in 
PBS). The slides were stained overnight in 0.5 mg/ml X-gal, 5 mM potas-
sium ferrocyanide, and 5 mM potassium ferricyanide in lacZ wash buff  er at 
37°C. After staining, the slides were rinsed with PBS and counterstained 
with nuclear fast red.
C3GnT activity assay. C3GnT activity was measured using GalNAcα1-
O-p-Nitrophenyl (GalNAcα-pNP; Sigma-Aldrich) as an acceptor following 
the established methods, with minor modifi  cations (22). In brief, the assay 
was performed in a 50-μl reaction containing 50 mM Tris-HCl, pH 7.0, 
2 mM GalNAcα-pNP, 200 μM UDP-[3H]GlcNAc (60,000–90,000 cpm; 
PerkinElmer Life Science), 20 mM MnCl2, 0.1% Triton X-100, and 100 μg 
protein from tissue extracts from C3GnT+/+ and C3GnT−/− mice. The re-
actions were incubated at 37°C for 1 h and stopped by adding 950 μl cold 
H2O. The products were separated from free UDP-[3H]GlcNAc by Sep-Pak 
(C18) column chromatography and quantifi  ed.
Expression of soluble recombinant epitope-tagged C3GnT. The pu-
tative catalytic domain of mouse C3GnT was amplifi   ed by PCR using 
mouse colon cDNA as a template and cloned into a baculovirus expression 
vector that contains DNA sequence encoding a signal peptide and a human 
protein C epitope, which is recognized by a Ca2+-dependent mAb (HPC4), 
upstream of the inserted C3GnT sequence (21). Sf9 insect cells transfected 
with the vector and an empty vector were used to produce high-titer viral 
stocks. High Five insect cells grown in serum-free medium at 27°C were 
infected by the recombinant viruses for 72 h. The soluble recombinant 
C3GnT was purifi  ed from the conditioned medium using a HPC4-Ultra-
Link resin column. 100 ng of purifi  ed, epitope-tagged C3GnT or 20 μl of 
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(4–20%), transferred to a nitrocellulose membrane, and detected with the 
HPC4 antibody.
Histology. For histological analysis, organs from C3GnT+/+ and C3GnT−/− 
mice were fi  xed in 10% formalin, processed, and embedded in paraffi   n. 
5-μm-thick tissue sections were stained with hematoxylin and eosin. In an-
other experiment, PAS (Sigma-Aldrich) and Alcian blue (Newcomer Supply) 
were used to stain general intestinal carbohydrate moieties. Transmission 
electron microscopy was performed as previously described (22).
Intestinal glycan structure analysis. The analysis was performed follow-
ing our published protocol (24). In brief, intestinal mucus, including the epi-
thelial cell layer, was collected by gently scraping the luminal surface of 
intestines from C3GnT+/+ and C3GnT−/− mice. Samples were dried and 
glycans were released by ammonia-based β elimination. The glycans were 
labeled with 2-aminobenzamide (2-AB) and separated by a phase column 
(4.6 × 250 mm; Zorbax NH2; Agilent Technologies) using HPLC equipped 
with a fl  uorescence detector (Ex 330 nm and Em 420 nm). O-glycans la-
beled with 2-AB were collected from the HPLC and analyzed for structure 
composition using matrix-assisted laser desorption/ionization time-of-fl  ight 
mass spectrometry (MALDI-TOF-MS; Applied Biosystem) in a linear posi-
tive mode. All acquired spectra were smoothed by applying a 19-point 
Savitzky-Golay smoothing routine. The matrix used for the positive mode 
was 10 mg/ml 2,5-dihydroxybenzoic acid prepared in 50% acetonitrile and 
0.1% trifl  uoroacetic acid.
In vivo intestinal permeability. We used an established method to deter-
mine if the loss of O-glycans increases intestinal barrier permeability (57). In 
brief, C3GnT+/+ and C3GnT−/− mice were administered 200 μl of FITC-
dextran (600 mg/kg body weight; 4 kD; Sigma-Aldrich) by gavage. Blood 
was collected 4 h later by retroorbital bleeding. The serum concentration of 
the FITC-dextran was determined using a fl  uorimeter (PerkinElmer Life 
Sciences) with an excitation wavelength at 490 nm and an emission wave-
length of 530 nm. Serial-diluted FITC-dextran was used to generate a stan-
dard curve. In another experiment, mice were treated with FITC-dextran as 
described above, and cryosections of the small intestines and colons were 
prepared for fl  uorescence microscopy.
Real-time PCR. Two sets of universal primers specifi  c for the conserved 
regions of the bacterial 16S rDNA gene were used (58–60). These in-
cluded 16S1 (forward, 5′-C  C  A  T  G  A  A  G  T  C  G  G  A  A  T  C  G  C  T  A  G  -3′; reverse, 
5′-A  C  T  C  C  C  A  T  G  G  T  G  T  G  A  C  G  G  -3′) and 16S2 (forward, 5′-T  C  C  T  A  C-
G  G  G  A  G  G  C  A  G  C  A  G  T  -3′; reverse, 5′-G  G  A  C  T  A  C  C  A  G  G  G  T  A  T  C  T  A  A-
T  C  C  T  G  T  T  -3′). DNA extracted from colonic tissues and colonic fecal 
mate  rials were used as a template. Colonic tissues were washed carefully before 
extraction of DNA to remove residual feces. For the quantifi  cation of fecal 
bacterial 16S rDNA, DNA from each mouse fecal sample was quantifi  ed, 
and 2.5 pg DNA was used as a template in each PCR reaction. For the 
quantifi  cation of 16S rDNA in colonic tissues, a pair of primers specifi  c to the 
mouse P-selectin gene (forward, 5′-A  T  G  A  T  T  A  G  C  A  A  A  T  T  C  T  A  G  C  T  C  C-
T  G  T  T  T  -3′; reverse, 5′-T  A  G  G  T  C  T  C  T  T  A  G  G  A  T  C  T  C  C  C  T  T  C  A  A  T  -3′) 
was used in a separate reaction as the endogenous control to normalize the 
DNA loading between samples. Real-time PCR was performed on an ABI 
Prism 7000 spectrofluorometric thermal cycler (Applied Biosystems) 
using SYBR-green as a double-stranded DNA–specifi  c binding dye. The re-
lative amount of 16S rDNA in each sample was estimated using the ∆∆CT 
method following the manufacturer’s protocol. Each sample was assayed 
in duplicate.
Immunohistochemistry. To characterize intestinal infl  ammatory cell in-
fi  ltrates, cryosections of colons from C3GnT−/− and C3GnT+/+ mice were 
fi  rst incubated with a hamster polyclonal antibody to the lymphocyte marker, 
CD3 (1:50 dilution; BD Biosciences), or a rat mAb to the macrophage 
marker, F4/80 (1:200 dilution; Accurate Chemical and Scientifi  c Co.) for 1 h 
at room temperature. The sections were then incubated for 30 min with 
  biotin-conjugated anti–hamster or rat IgG, and subsequently incubated for 
30 min with fl  uorescein isothiocyanate–conjugated avidin D or Texas red 
avidin D (Vector Laboratories), respectively. The sections were mounted 
with Vectashield mounting medium (Vector Laboratories) and analyzed by 
a fl  uorescent microscope (ECLIPSE E600; Nikon).
For immunohistochemical detection of Muc2, ITF, and β-catenin, de-
paraffi   nized sections were boiled for 20 min in 0.01 M citrate buff  er, pH 6.0, 
for epitope retrieval. The sections were then blocked for 20 min using a 
protein blocking kit (DakoCytomation) for nonspecifi  c antibody binding. 
Endogenous avidin-binding proteins were blocked using avidin/biotin 
blocking reagents (Vector Laboratories). Sections were incubated overnight 
at 4°C with rabbit anti-Muc2 antibody (1:200; Santa Cruz Biotechnologies), 
with goat anti-ITF antibody (1:200; Santa Cruz Biotechnologies), with 
mouse anti–β-catenin mAb (1:500; Transduction Laboratories), or with 
isotype-matched control IgG, respectively. The sections were subsequently 
incubated with biotinylated anti–rabbit, –goat, or –mouse IgG antibodies 
(Vector Laboratories) for 45 min, followed by a 20-min incubation with 
0.6% H2O2 in methanol to inhibit endogenous peroxidase activity. The sec-
tions were fi  nally incubated with horseradish peroxidase (HRP)-streptavidin 
(Vector Laboratories) for 30 min, and then developed with a diaminobenzi-
dine substrate and counterstained with hemotoxylin.
For Tn antigen staining, deparaffi   nized sections were incubated with 
or without 0.5 U/ml sialidase from Arthrobacter ureafaciens (Roche) at 37°C 
for 3 h. Sections were incubated for 30 min with biotinylated mAb against 
the Tn antigen (mouse IgG) or with isotype-matched control mouse IgG. 
Bound antibodies were detected with HRP-conjugated streptavidin (Vector 
Laboratories).
Immunoblots. Colon extracts (40 μg of total protein) from C3GnT−/−and 
C3GnT+/+ mice were resolved by SDS-PAGE under reducing conditions 
and transferred to a nitrocellulose membrane (Bio-Rad Laboratories). The 
membrane was blocked with 5% nonfat dry milk overnight and incubated 
with a rabbit polyclonal antibody to β-catenin (Lab Vision Corp.), a mouse 
mAb to TCF-4 (Millipore), a rabbit polyclonal antibody to c-myc (Santa 
Cruz Biotechnologies), a mouse mAb to cyclin D1 (BD Biosciences), or an 
anti–β-actin antibody (Affi   nity BioReagents) for loading control. Binding 
was detected with HRP-conjugated anti–rabbit or –mouse IgG (Vector 
Laboratories) using enhanced chemiluminescence (GE Healthcare).
DSS-induced colitis model. To determine the lethality of DSS, mice 
were fed 2.5% DSS (40 kD; MP Biomedicals, Inc.) in drinking water for 14 d. 
To induce colitis, C3GnT+/+ and C3GnT−/− males were treated with 2% 
DSS dissolved in drinking water for 7 d, followed by 4 d of regular water. 
Mice were then killed for histological analysis.
Body weight, the presence of occult or gross blood per rectum, stool 
consistency, and mortality were monitored daily during the course of treatments. 
The clinical score was assessed based on these measurements and determined 
according to a published method (61). Histological scoring was performed in 
a blinded fashion as a combined score of infl  ammatory cell infi  ltration and 
tissue damage (61).
Intracellular cytokine staining. Intracellular cytokine staining was per-
formed to assess the level of cytokines produced by the lymphocytes from 
the spleens of DSS-treated C3GnT+/+ and C3GnT−/− mice, as well as in-
testinal mucosal lymphocytes from C3GnT+/+ and C3GnT−/− mice with-
out DSS treatment.
In brief, splenocytes were isolated from DSS-treated C3GnT+/+ and 
C3GnT−/− mice after lysis of erythrocytes with ACK Lysis Buff  er (Cambrex 
Bio Science). Intestinal IELs and LPLs were isolated from the large intestines 
of C3GnT+/+ and C3GnT−/− males (129/SvlmJ background), as previously 
described with minor modifi  cations (62). For intracellular cytokine staining, 
isolated lymphocytes were activated with Leukocyte Activation Cocktail 
containing BD GolgiPlug (BD Biosciences) at 5 × 105 cells/well in 96-well 
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harvested for surface and intracellular cytokine staining. Surface staining 
of the cells was performed by incubating with FITC-, APC-, and PerCP-
conjugated mAbs specifi  c to CD3, CD4, and CD19 for 30 min on ice. After 
surface staining, the cells were fi  xed and permeabilized for 20 min at room 
temperature using BD Cytofi  x/Cytoperm buff  er and washed twice with the 
BD Perm/Wash buff  er (both BD Biosciences). Intracellular cytokine stain-
ing was performed by incubating with the PE-conjugated antibodies against 
murine IL-2, -6, -10, -12, -17, TNF-α, and IFN-γ on ice for 15 min. The 
cells were washed three times with BD Perm/Wash buff  er and analyzed with 
a FACSCalibur fl  ow cytometer (BD Biosciences).
AOM/DSS-induced mouse colorectal tumorogenesis model. 6-wk-
old C3GnT+/+ and C3GnT−/− males were given a single intraperitoneal in-
jection of AOM (10 mg/kg body weight; Sigma-Aldrich) (34). Starting 1 wk 
after injection, mice were fed with 1.75% DSS in drinking water for 7 d and 
then received no further treatment. Mice were killed for histopathological 
analysis 12 or 20 wk after the 7-d DSS treatment. The colon was cut open 
longitudinally and examined for the presence of tumors. The number and 
size of tumors were recorded. The tumor volumes were determined by mea-
suring the length (l) and the width (w) and calculated volume (V = lw  2/2), 
as previously described (63). Tissues were fi  xed in 10% formalin and embed-
ded in paraffi   n for histopathological analysis. Fresh colonic tissue lysates from 
C3GnT+/+ and C3GnT−/− mice with or without AOM/DSS treatments 
were prepared for Western blot analysis.
In vivo BrdU labeling assay. Mice were injected intraperitoneally with 
BrdU (20 mg/kg of body weight; Sigma-Aldrich) (25). 3 h after BrdU injec-
tion, mice were killed, and colonic tissues were processed for immunochem-
ical analysis. Incorporation of BrdU in proliferating intestinal epithelial cells 
was detected with a rat mAb to BrdU (1:100 dilution; Accurate Chemical 
and Scientifi  c Co.). The number of BrdU-positive cells per crypt column 
was quantifi  ed.
Statistical analysis. Data were analyzed by the Student’s t test. The Wil-
coxon signed-rank test was used to compare data that did not satisfy the 
Student’s t test. P < 0.05 was considered signifi  cant.
Online supplemental material. Fig. S1 shows murine C3GnT genomic 
structure and deduced protein sequence. Fig. S2 shows characterization of 
murine C3GnT. Fig. S3 presents histology (hematoxylin and eosin stain) of 
C3GnT+/+ and C3GnT−/− small intestines from 6-wk-old mice. Fig. S4 
demonstrates that the immune organs and immune cells develop normally 
in C3GnT−/− mice. Fig. S5 shows MADI-TOF-MS standards of 2-AB–
labeled core 1 and core 3 O-glycans, as well as MALDI-TOF-MS of 2-AB–
labeled O-glycans of mouse colon and predicted compositions in a linear 
positive mode. Fig. S6 shows glycan expression profi  les in C3GnT+/+ and 
C3GnT−/− small intestines. Fig. S7 is an analysis of mRNA transcripts of 
diff  erent intestinal mucins from C3GnT+/+ and C3GnT−/− colons, as well 
as morphological comparisons of C3GnT+/+ and C3GnT−/− goblet cells. 
Fig. S8 compares colon length of C3GnT+/+ and C3GnT−/− mice after 
DSS-induced colitis. The online version of this article is available at http://
www.jem.org/cgi/content/full/jem.20061929/DC1.
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